EYPT Q3 2024 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M-30.8% YoY

Gross Profit

$10M93.0% margin

Operating Income

-$33M-311.2% margin

Net Income

-$29M-279.0% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+11.0%

Cash Flow

Operating Cash Flow

-$39M

Free Cash Flow

-$41M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$301M

Total Liabilities

$82M

Stockholders' Equity

$219M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$15M	-30.8%
Gross Profit	$10M	$14M	-30.1%
Operating Income	-$33M	-$14M	-127.4%
Net Income	-$29M	-$13M	-132.8%

Revenue Segments

License And Collaboration Agreement

$10M85%

Y U T I Q Product

$700,0006%

Product

$664,0006%

Royalty

$299,0003%